Product
QLS-101
4 clinical trials
4 indications
Indication
Sturge-Weber SyndromeIndication
GlaucomaIndication
ocular hypertensionIndication
Primary Open Angle GlaucomaClinical trial
A Randomized Active-controlled Study to Evaluate Safety and Tolerability of QLS-101 Versus Timolol Preservative Free (PF) Ophthalmic Solution in Subjects With Normal Tension Glaucoma (NTG)Status: Completed, Estimated PCD: 2022-08-26
Clinical trial
A Randomized Active-controlled Multi-site Double-masked Study to Evaluate the Safety and Tolerability of 3 Concentrations of QLS-101 Versus Timolol Maleate Preservative Free (PF) 0.5% Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular HypertensionStatus: Completed, Estimated PCD: 2022-02-17
Clinical trial
Pilot, Open-label Study of Safety and Tolerability of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)Status: Completed, Estimated PCD: 2023-01-25
Clinical trial
Masked, Randomized, Single-site, Crossover Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101 Dosed for 14 Days in Adult Subjects With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)Status: Completed, Estimated PCD: 2022-06-06